Dr. Reddy's Laboratories has wrapped up its acquisition of GlaxoSmithKline's U.S. oral penicillin facility and product portfolio.


Dr. Reddy's Laboratories, GlaxoSmithKline, oral penicillin facility, oral penicillin, Augmentin, Amoxil, antibiotic, Bristol, penicillin manufacturing site, Abhijit Mukherjee, generics business














































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

GSK penicillin acquisition closed by Dr. Reddy's

March 30th, 2011

HYDERABAD, India – Dr. Reddy's Laboratories has wrapped up its acquisition of GlaxoSmithKline's U.S. oral penicillin facility and product portfolio.

With the deal, which was announced last November, Dr. Reddy's takes over the GlaxoSmithKline's penicillin manufacturing site in Bristol, Tenn., as well as assumes the rights for the Augmentin and Amoxil antibiotic brands in the United States.

According to Dr. Reddy's, GlaxoSmithKline will retain the existing rights for the Augmentin and Amoxil brands outside the United States.

Financial terms of the acquisition weren't disclosed.

"This acquisition is in line with our strategy to significantly scale up our generics business in North America while providing an opportunity to explore additional synergy with our other businesses," Abhijit Mukherjee, president of global generics business for Dr. Reddy's, stated when the deal was unveiled last fall.

Advertisement